

# Kenneth I Kaitin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5593391/kenneth-i-kaitin-publications-by-citations.pdf>

**Version:** 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9  
papers

114  
citations

7  
h-index

10  
g-index

14  
ext. papers

164  
ext. citations

14.1  
avg, IF

3.01  
L-index

#	Paper	IF	Citations
9	The evolution of biotechnology and its impact on health care. <i>Health Affairs</i> , <b>2015</b> , 34, 210-9	7	26
8	Variability in Protocol Design Complexity by Phase and Therapeutic Area. <i>Drug Information Journal</i> , <b>2011</b> , 45, 413-420		19
7	Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 1409-1425.e20	3.5	15
6	Translational research and the evolving landscape for biomedical innovation. <i>Journal of Investigative Medicine</i> , <b>2012</b> , 60, 995-8	2.9	12
5	Reforming China's drug regulatory system. <i>Nature Reviews Drug Discovery</i> , <b>2018</b> , 17, 858-859	64.1	10
4	Regulatory watch: Innovative drug availability in China. <i>Nature Reviews Drug Discovery</i> , <b>2016</b> , 15, 739-740	64.1	8
3	Taking the pulse of strategic outsourcing relationships. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 1349-55	3.5	7
2	The Landscape for Pharmaceutical Innovation: Drivers of Cost-Effective Clinical Research <b>2010</b> , 2010,		6
1	A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2021</b> , 55, 676-684	1.2	1